Medicines on the FDA drug shortage list, with which forms and strengths are affected, who makes them and when supply is expected back.
240 medicines
-
Hydromorphone Hydrochloride In shortage Some forms unavailable 27 products · updated October 21, 2026
Analgesia/Addiction
Product Availability Expected supply / notes Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)
Hospira, Inc., a Pfizer CompanyUnavailable Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)
Hospira, Inc., a Pfizer CompanyUnavailable Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)
Fresenius Kabi USA, LLCUnavailable Next release October 2026. Check wholesalers for inventory.
In shortage · October 15, 2026Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)
Fresenius Kabi USA, LLCUnavailable Next release October 2026. Check wholesalers for inventory.
In shortage · October 15, 2026Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)
Fresenius Kabi USA, LLCUnavailable Next release October 2026. Check wholesalers for inventory.
In shortage · October 15, 2026Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)
Fresenius Kabi USA, LLCUnavailable Next release not available at this time. Check wholesalers for inventory.
In shortage · October 15, 2026Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)
Hikma Pharmaceuticals USA, Inc.Unavailable Product temporarily on backorder. Additional lots will be available in the November 2026 timeframe.
In shortage · October 14, 2026Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)
Hospira, Inc., a Pfizer CompanyLimited Limited Supply Available. Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)
Hospira, Inc., a Pfizer CompanyLimited Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03)
Teva Pharmaceuticals USA, Inc.Limited Estimated recovery: October 2026
In shortage · October 15, 2026Hydromorphone Hydrochloride, Suppository, 3 mg (NDC 0574-7224-06)
Padagis US LLCDiscontinuation of the manufacture of the drug
Being discontinued · July 23, 2026+ 16 more products listed, currently available.
-
Ketorolac Tromethamine In shortage Some forms unavailable 26 products · updated October 21, 2026
Analgesia/Addiction
Product Availability Expected supply / notes Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)
Hospira, Inc., a Pfizer CompanyUnavailable Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)
Hospira, Inc., a Pfizer CompanyUnavailable Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)
Hospira, Inc., a Pfizer CompanyUnavailable Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)
Baxter HealthcareUnavailable Estimated recovery: December 2026
In shortage · October 16, 2026Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)
Fresenius Kabi USA, LLCUnavailable Next release not available at this time. Check wholesalers for inventory.
In shortage · October 15, 2026Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)
Fresenius Kabi USA, LLCUnavailable Estimated recovery: TBD
In shortage · October 15, 2026Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)
Fresenius Kabi USA, LLCUnavailable Next release not available at this time. Check wholesalers for inventory.
In shortage · October 15, 2026Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)
Fresenius Kabi USA, LLCUnavailable Estimated recovery: TBD
In shortage · October 15, 2026Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)
Fresenius Kabi USA, LLCUnavailable Estimated recovery: TBD
In shortage · October 15, 2026Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)
Hikma Pharmaceuticals USA, Inc.Unavailable Estimated recovery: TBD
In shortage · October 14, 2026Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)
Hikma Pharmaceuticals USA, Inc.Unavailable Estimated recovery: TBD
In shortage · October 14, 2026Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)
Hikma Pharmaceuticals USA, Inc.Unavailable Estimated recovery: TBD
In shortage · October 14, 2026Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)
Sagent PharmaceuticalsLimited Estimated recovery: end-October to mid-November 2026
In shortage · October 8, 2026Ketorolac Tromethamine, Tablet, 10 mg (NDC 0378-1134-01)
Mylan Pharmaceuticals Inc., a Viatris CompanyDiscontinuation of the manufacture of the drug
Being discontinued · April 20, 2026+ 12 more products listed, currently available.
-
Lidocaine Hydrochloride In shortage Some forms unavailable 68 products · updated October 21, 2026
Anesthesia, Pediatric, Cardiovascular, Analgesia/Addiction
Product Availability Expected supply / notes Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32)
Hospira, Inc., a Pfizer CompanyUnavailable Next Delivery and Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)
Hospira, Inc., a Pfizer CompanyUnavailable Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)
Eugia US LLCUnavailable On backorder. Recovery: late-November 2026; Check wholesalers for inventory
In shortage · October 19, 2026Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)
Eugia US LLCUnavailable On backorder. Recovery: TBD. Check wholesalers for inventory
In shortage · October 19, 2026Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)
Eugia US LLCUnavailable On backorder. Recovery: TBD. Check wholesalers for inventory
In shortage · October 19, 2026Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)
Eugia US LLCUnavailable On backorder. Recovery: mid-November 2026; Check wholesalers for inventory
In shortage · October 19, 2026Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)
Eugia US LLCUnavailable On backorder. Recovery: late October 2026; Check wholesalers for inventory
In shortage · October 19, 2026Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)
Fresenius Kabi USA, LLCUnavailable Estimated recovery: TBD
In shortage · October 15, 2026Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)
Fresenius Kabi USA, LLCUnavailable Estimated recovery: TBD
In shortage · October 15, 2026Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)
Fresenius Kabi USA, LLCUnavailable Next release November 2026. Check wholesalers for inventory.
In shortage · October 15, 2026Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)
Fresenius Kabi USA, LLCUnavailable Estimated recovery: TBD
In shortage · October 15, 2026Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)
Fresenius Kabi USA, LLCUnavailable Estimated recovery: TBD
In shortage · October 15, 2026Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)
Fresenius Kabi USA, LLCUnavailable Next release October 2026. Check wholesalers for inventory.
In shortage · October 15, 2026Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)
Fresenius Kabi USA, LLCUnavailable Next release October 2026. Check wholesalers for inventory.
In shortage · October 15, 2026Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)
Fresenius Kabi USA, LLCUnavailable Next release November 2026. Check wholesalers for inventory.
In shortage · October 15, 2026Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)
Fresenius Kabi USA, LLCUnavailable Estimated recovery: TBD
In shortage · October 15, 2026Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)
Hikma Pharmaceuticals USA, Inc.Unavailable Product temporarily on backorder. Additional lots will be available in the November 2026 timeframe.
In shortage · October 14, 2026Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)
Huons Co., Ltd. (South Korea)Unavailable Estimated recovery: TBD
In shortage · July 30, 2026Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)
Hospira, Inc., a Pfizer CompanyLimited Limited Supply Available. Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Lidocaine Hydrochloride, Injection, 1%, USP (For Cardiac Use Only) 50 mg/5 mL (10 mg/mL) LifeShield™ ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4904-34)"
Hospira, Inc., a Pfizer CompanyDiscontinuation of the manufacture of the drug
Being discontinued · November 7, 2025Lidocaine Hydrochloride, Injection, 2%, USP (For Cardiac Use Only) 100 mg/5 mL (20 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4903-34)"
Hospira, Inc., a Pfizer CompanyDiscontinuation of the manufacture of the drug
Being discontinued · November 7, 2025+ 47 more products listed, currently available.
-
Lorazepam In shortage Some forms unavailable 11 products · updated October 21, 2026
Neurology
Product Availability Expected supply / notes Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)
Hikma Pharmaceuticals USA, Inc.Unavailable Estimated recovery: TBD
In shortage · October 14, 2026Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)
Hikma Pharmaceuticals USA, Inc.Unavailable Estimated recovery: TBD
In shortage · October 14, 2026Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)
Hikma Pharmaceuticals USA, Inc.Unavailable Estimated recovery: TBD
In shortage · October 14, 2026Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)
Hikma Pharmaceuticals USA, Inc.Unavailable Estimated recovery: TBD
In shortage · October 14, 2026Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)
Hospira, Inc., a Pfizer CompanyLimited Limited Supply Available. Next Delivery and Estimated Recovery: June 2027
In shortage · October 21, 2026Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)
Hikma Pharmaceuticals USA, Inc.Limited Additional lots are scheduled to be manufactured. Product will be made available as it is released.
In shortage · October 14, 2026Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)
Hikma Pharmaceuticals USA, Inc.Limited Additional lots are scheduled to be manufactured. Product will be made available as it is released.
In shortage · October 14, 2026Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)
Hikma Pharmaceuticals USA, Inc.Limited Additional lots are scheduled to be manufactured. Product will be made available as it is released.
In shortage · October 14, 2026Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)
Hikma Pharmaceuticals USA, Inc.Limited Additional lots are scheduled to be manufactured. Product will be made available as it is released.
In shortage · October 14, 2026+ 2 more products listed, currently available.
-
Meperidine Hydrochloride In shortage 6 products · updated October 21, 2026
Analgesia/Addiction
Product Availability Expected supply / notes Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)
Hospira, Inc., a Pfizer CompanyAvailable —
In shortage · October 21, 2026Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)
Hospira, Inc., a Pfizer CompanyAvailable —
In shortage · October 21, 2026Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)
Hospira, Inc., a Pfizer CompanyAvailable —
In shortage · October 21, 2026Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)
Hikma Pharmaceuticals USA, Inc.Available Additional lots are scheduled to be manufactured. Product will be made available as it is released.
In shortage · October 14, 2026Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)
Hikma Pharmaceuticals USA, Inc.Available Additional lots are scheduled to be manufactured. Product will be made available as it is released.
In shortage · October 14, 2026Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)
Hikma Pharmaceuticals USA, Inc.Available Additional lots are scheduled to be manufactured. Product will be made available as it is released.
In shortage · October 14, 2026 -
Methylprednisolone Acetate In shortage Some forms unavailable 23 products · updated October 21, 2026
Rheumatology
Product Availability Expected supply / notes Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)
Pfizer Inc.Unavailable Next Delivery: November 2026; Estimated Recovery: December 2026
In shortage · October 21, 2026Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)
Eugia US LLCUnavailable On backorder. Recovery: TBD. Check wholesalers for inventory
In shortage · October 19, 2026Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)
Eugia US LLCUnavailable On backorder. Recovery: TBD. Check wholesalers for inventory
In shortage · October 19, 2026Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)
Par Health, USA LLCUnavailable Estimated recovery: TBD
In shortage · October 15, 2026Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)
Pfizer Inc.Limited Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)
Pfizer Inc.Limited Limited Supply Available. Next Delivery and Estimated Recovery: December 2026
In shortage · October 21, 2026Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)
Pfizer Inc.Limited Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)
Pfizer Inc.Limited Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026
In shortage · October 21, 2026Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)
Pfizer Inc.Limited Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026
In shortage · October 21, 2026Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)
Pfizer Inc.Limited Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)
Sagent PharmaceuticalsLimited Limited product available. Estimated recovery: October 2026
In shortage · October 8, 2026Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)
Sagent PharmaceuticalsLimited Estimated recovery: November 2026, Product on hand is 8-12 months of dating prior to expiry
In shortage · October 8, 2026Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)
Amneal PharmaceuticalsLimited Estimated recovery: late October 2026/November 2026
In shortage · October 6, 2026+ 10 more products listed, currently available.
-
Metronidazole In shortage Some forms unavailable 4 products · updated October 21, 2026
Anti-Infective
Product Availability Expected supply / notes Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)
Gland Pharma LimitedUnavailable Discontinuation of the manufacture of the drug
In shortage · October 21, 2026Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)
InfoRLife SALimited Labeler: Hospira Inc.
In shortage · October 6, 2026Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)
InfoRLife SALimited Estimated recovery: November 2026; Marketed by Sagent Pharmaceuticals
In shortage · October 6, 2026+ 1 more product listed, currently available.
-
Morphine Sulfate In shortage Some forms unavailable 30 products · updated October 21, 2026
Analgesia/Addiction
Product Availability Expected supply / notes Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-2022-01)
Hospira, Inc., a Pfizer CompanyUnavailable Next Delivery: February 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)
Hospira, Inc., a Pfizer CompanyUnavailable Next Delivery: February 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)
Hospira, Inc., a Pfizer CompanyUnavailable Discontinuation of the manufacture of the drug
In shortage · October 21, 2026Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)
Fresenius Kabi USA, LLCUnavailable Next release November 2026. Check wholesalers for inventory.
In shortage · October 15, 2026Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)
Fresenius Kabi USA, LLCUnavailable Estimated recovery: TBD
In shortage · October 15, 2026Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)
Hikma Pharmaceuticals USA, Inc.Unavailable Additional lots will be available in the November 2026 timeframe. Product will be made available as it is released.
In shortage · October 14, 2026Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)
Hospira, Inc., a Pfizer CompanyLimited Limited Supply Available. Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)
Hospira, Inc., a Pfizer CompanyLimited Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Morphine Sulfate, Suppository, 30 mg (NDC 0574-7116-12)
Padagis US LLCDiscontinuation of the manufacture of the drug
Being discontinued · July 23, 2026Morphine Sulfate, Suppository, 20 mg (NDC 0574-7114-12)
Padagis US LLCDiscontinuation of the manufacture of the drug
Being discontinued · July 23, 2026Morphine Sulfate, Suppository, 5 mg (NDC 0574-7110-12)
Padagis US LLCDiscontinuation of the manufacture of the drug
Being discontinued · July 23, 2026Morphine Sulfate, Suppository, 10 mg (NDC 0574-7112-12)
Padagis US LLCDiscontinuation of the manufacture of the drug
Being discontinued · July 23, 2026Morphine Sulfate, Tablet, 15 mg (NDC 0832-0273-11)
Upsher-Smith Laboratories, LLCDiscontinuation of the manufacture of the drug
Being discontinued · December 22, 2025Morphine Sulfate, Tablet, 30 mg (NDC 0832-0274-11)
Upsher-Smith Laboratories, LLCDiscontinuation of the manufacture of the drug
Being discontinued · December 22, 2025+ 16 more products listed, currently available.
-
Penicillin G Benzathine In shortage Some forms unavailable 3 products · updated October 21, 2026
Anti-Infective
Product Availability Expected supply / notes Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)
Pfizer Inc.Unavailable Next Delivery: October 2027; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)
Pfizer Inc.Limited Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: September 2027; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)
Pfizer Inc.Limited Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: September 2027; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026 -
Pentostatin In shortage Some forms unavailable 1 product · updated October 21, 2026
Oncology
Product Availability Expected supply / notes Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01)
Hospira, Inc., a Pfizer CompanyUnavailable Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026 -
Rocuronium Bromide In shortage Some forms unavailable 24 products · updated October 21, 2026
Anesthesia
Product Availability Expected supply / notes Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)
Fresenius Kabi USA, LLCUnavailable Next release December 2026. Check wholesalers for inventory.
In shortage · October 15, 2026Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-444-10)
Fresenius Kabi USA, LLCUnavailable Next release November 2026. Check wholesalers for inventory.
In shortage · October 15, 2026Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)
Fresenius Kabi USA, LLCUnavailable Next release November 2026. Check wholesalers for inventory.
In shortage · October 15, 2026Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)
Fresenius Kabi USA, LLCUnavailable Estimated recovery: TBD
In shortage · October 15, 2026+ 20 more products listed, currently available.
-
Sodium Acetate In shortage Some forms unavailable 13 products · updated October 21, 2026
Endocrinology/Metabolism, Gastroenterology, Pediatric, Total Parenteral Nutrition
Product Availability Expected supply / notes Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00)
Fresenius Kabi USA, LLCUnavailable Next release November 2026. Check wholesalers for inventory.
In shortage · October 15, 2026Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10)
Milla PharmaceuticalsLimited Estimated recovery: TBD
In shortage · October 15, 2026+ 11 more products listed, currently available.
-
Sodium Bicarbonate In shortage Some forms unavailable 15 products · updated October 21, 2026
Endocrinology/Metabolism, Gastroenterology, Pediatric
Product Availability Expected supply / notes Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)
Hospira, Inc., a Pfizer CompanyUnavailable Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)
Hospira, Inc., a Pfizer CompanyLimited Limited Supply Available. Next Delivery: February 2027; Estimated Recovery: March 2027
In shortage · October 21, 2026Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)
Hospira, Inc., a Pfizer CompanyLimited Limited Supply Available. Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)
Amphastar Pharmaceuticals, Inc.Limited Available on allocation
In shortage · October 16, 2026Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-4900-14)
Hospira, Inc., a Pfizer CompanyDiscontinuation of the manufacture of the drug
Being discontinued · November 7, 2025Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 0409-5534-14)
Hospira, Inc., a Pfizer CompanyDiscontinuation of the manufacture of the drug
Being discontinued · November 7, 2025Sodium Bicarbonate, Injection, 75 mg/1 mL (NDC 0409-4916-14)
Hospira, Inc., a Pfizer CompanyDiscontinuation of the manufacture of the drug
Being discontinued · November 7, 2025Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-6637-14)
Hospira, Inc., a Pfizer CompanyDiscontinuation of the manufacture of the drug
Being discontinued · November 7, 2025+ 7 more products listed, currently available.
-
Sufentanil Citrate In shortage Some forms unavailable 4 products · updated October 21, 2026
Analgesia/Addiction, Pediatric
Product Availability Expected supply / notes Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)
Hikma Pharmaceuticals USA, Inc.Unavailable Not currently manufactured
In shortage · October 14, 2026Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)
Hikma Pharmaceuticals USA, Inc.Unavailable Not currently manufactured
In shortage · October 14, 2026Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)
Hikma Pharmaceuticals USA, Inc.Unavailable Not currently manufactured
In shortage · October 14, 2026Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)
Hospira, Inc., a Pfizer CompanyLimited Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
In shortage · October 21, 2026 -
Azacitidine In shortage Some forms unavailable 9 products · updated October 20, 2026
Oncology
Product Availability Expected supply / notes Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)
Eugia US LLCUnavailable On backorder. Recovery: TBD. Check wholesalers for inventory
In shortage · October 19, 2026Azacitidine, Injection, 100 mg (NDC 68001-313-56)
Teva Pharmaceuticals USA, Inc.Unavailable Estimated recovery: TBD
In shortage · October 15, 2026Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)
Fresenius Kabi USA, LLCUnavailable Discontinuation of the manufacture of the drug
In shortage · October 15, 2026Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)
Hikma Pharmaceuticals USA, Inc.Unavailable Product temporarily on backorder. Additional lots will be available the end of October 2026.
In shortage · October 14, 2026Azacitidine, Injection, 100 mg (NDC 72485-201-01)
Armas Pharmaceuticals IncLimited Estimated recovery: TBD
In shortage · June 8, 2026+ 4 more products listed, currently available.
-
Enoxaparin Sodium Being discontinued 24 products · updated October 20, 2026
Hematology
Product Availability Expected supply / notes Lovenox, Injection, 60 mg/.6 mL (NDC 0075-0621-60)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Lovenox, Injection, 300 mg/3 mL (NDC 0075-8030-01)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Lovenox, Injection, 150 mg/1 mL (NDC 0075-2915-01)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Lovenox, Injection, 40 mg/.4 mL (NDC 0075-8014-10)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Lovenox, Injection, 80 mg/.8 mL (NDC 0075-0622-80)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Enoxaparin Sodium, Injection, 30 mg/.3 mL (NDC 0955-1003-10)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Lovenox, Injection, 30 mg/.3 mL (NDC 0075-0624-30)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Enoxaparin Sodium, Injection, 60 mg/.6 mL (NDC 0955-1006-10)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Lovenox, Injection, 80 mg/.8 mL (NDC 0075-8018-10)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Lovenox, Injection, 30 mg/.3 mL (NDC 0075-8013-10)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Enoxaparin Sodium, Injection, 120 mg/.8 mL (NDC 0955-1012-10)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Lovenox, Injection, 60 mg/.6 mL (NDC 0075-8016-10)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Enoxaparin Sodium, Injection, 100 mg/1 mL (NDC 0955-1010-10)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Lovenox, Injection, 120 mg/.8 mL (NDC 0075-8022-10)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Lovenox, Injection, 100 mg/1 mL (NDC 0075-8020-10)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Lovenox, Injection, 300 mg/3 mL (NDC 0075-0626-03)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Enoxaparin Sodium, Injection, 150 mg/1 mL (NDC 0955-1015-10)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Lovenox, Injection, 150 mg/1 mL (NDC 0075-8025-10)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Lovenox, Injection, 100 mg/1 mL (NDC 0075-0623-00)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Enoxaparin Sodium, Injection, 40 mg/.4 mL (NDC 0955-1004-10)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Lovenox, Injection, 40 mg/.4 mL (NDC 0075-0620-40)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Enoxaparin Sodium, Injection, 300 mg/3 mL (NDC 0955-1016-01)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Enoxaparin Sodium, Injection, 80 mg/.8 mL (NDC 0955-1008-10)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026Lovenox, Injection, 120 mg/.8 mL (NDC 0075-2912-01)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Being discontinued · October 20, 2026 -
Leuprolide Acetate Being discontinued 1 product · updated October 20, 2026
Oncology
Product Availability Expected supply / notes Leuprolide Acetate, Injection, 14 mg/2.8 mL (1 mg/0.2 mL) (NDC 70121-2537-6)
Amneal PharmaceuticalsA business decision was made to discontinue manufacture of the drug.
Being discontinued · October 20, 2026 -
Methylphenidate Hydrochloride In shortage Some forms unavailable 34 products · updated October 20, 2026
Psychiatry
Product Availability Expected supply / notes Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)
Sun Pharmaceutical Industries, Inc.Unavailable Currently not marketed
In shortage · October 19, 2026Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)
Sun Pharmaceutical Industries, Inc.Unavailable Currently not marketed
In shortage · October 19, 2026Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)
Sun Pharmaceutical Industries, Inc.Unavailable Currently not marketed
In shortage · October 19, 2026Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)
Sun Pharmaceutical Industries, Inc.Unavailable Currently not marketed
In shortage · October 19, 2026Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)
Lannett Company, Inc.Unavailable Estimated recovery: November 2026
In shortage · October 15, 2026Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)
Lannett Company, Inc.Unavailable Estimated recovery: November 2026
In shortage · October 15, 2026Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)
Trigen Laboratories, LLCLimited Allocation to current contracted customers
In shortage · October 16, 2026Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)
Trigen Laboratories, LLCLimited Allocation to current contracted customers
In shortage · October 16, 2026Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)
Trigen Laboratories, LLCLimited Allocation to current contracted customers
In shortage · October 16, 2026Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)
Trigen Laboratories, LLCLimited Allocation to current contracted customers
In shortage · October 16, 2026Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)
Trigen Laboratories, LLCLimited Allocation to current contracted customers
In shortage · October 16, 2026Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)
Trigen Laboratories, LLCLimited Allocation to current contracted customers
In shortage · October 16, 2026Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)
Trigen Laboratories, LLCLimited Allocation to current contracted customers
In shortage · October 16, 2026Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01)
Teva Pharmaceuticals USA, Inc.Limited Estimated recovery: October 2026
In shortage · October 15, 2026Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01)
Teva Pharmaceuticals USA, Inc.Limited Estimated recovery: October 2026
In shortage · October 15, 2026+ 19 more products listed, currently available.
-
Molnupiravir Being discontinued 3 products · updated October 20, 2026
Anti-Infective, Antiviral
Product Availability Expected supply / notes Lagevrio, Capsule, 200 mg (NDC 0006-5055-06)
Merck Sharp & Dohme LLCDiscontinuation of the manufacture of the drug
Being discontinued · October 20, 2026Lagevrio, Capsule, 200 mg (NDC 0006-5055-07)
Merck Sharp & Dohme LLCDiscontinuation of the manufacture of the drug
Being discontinued · October 20, 2026Lagevrio, Capsule, 200 mg (NDC 0006-5055-09)
Merck Sharp & Dohme LLCDiscontinuation of the manufacture of the drug
Being discontinued · October 20, 2026 -
Cromolyn Sodium In shortage 4 products · updated October 19, 2026
Pulmonary/Allergy
Product Availability Expected supply / notes Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)
Mylan Specialty, a Viatris CompanyAvailable —
In shortage · October 19, 2026Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52)
Micro Labs LTDAvailable —
In shortage · October 16, 2026Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96)
Ailex PharmaceuticalsAvailable Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195
In shortage · September 30, 2026Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96)
Rising Pharma Holdings, Inc.Available —
In shortage · September 1, 2026 -
Hydroxocobalamin In shortage Some forms unavailable 2 products · updated October 19, 2026
Other
Product Availability Expected supply / notes Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30)
Teva Pharmaceuticals USA, Inc.Unavailable Estimated recovery: mid-November 2026
In shortage · October 15, 2026Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)
BTG International Inc.Limited Cyanokit is available to order. To address the drug shortage, BTG International Inc (a SERB Pharmaceuticals company) coordinated with the U.S. Food and Drug Administration (FDA) to make the following impacted batches available to U.S. patients during this period of shortage.
In shortage · October 19, 2026 -
Isoleucine, Leucine, Lysine Acetate, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Cysteine Hydrochloride, Histidine, Tyrosine, N-Acetyl-Tyrosine, Alanine, Arginine, Proline, Seri In shortage 1 product · updated October 19, 2026
Gastroenterology
Product Availability Expected supply / notes TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10)
B. Braun Medical Inc.Available —
In shortage · October 19, 2026 -
Lamivudine Being discontinued 2 products · updated October 19, 2026
Antiviral
Product Availability Expected supply / notes Epivir, Tablet, 150 mg (NDC 49702-203-18)
ViiV Healthcare CompanyThe anticipated date that ViiV will cease distribution of the products is approximately April 15, 2027; Discontinuation of the manufacture of the drug
Being discontinued · October 19, 2026Epivir, Tablet, 300 mg (NDC 49702-204-13)
ViiV Healthcare CompanyThe anticipated date that ViiV will cease distribution of the products is approximately April 15, 2027; Discontinuation of the manufacture of the drug
Being discontinued · October 19, 2026 -
Lisdexamfetamine In shortage 13 products · updated October 19, 2026
Psychiatry
Product Availability Expected supply / notes Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77)
Mylan Pharmaceuticals Inc., a Viatris CompanyAvailable —
In shortage · October 19, 2026Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77)
Mylan Pharmaceuticals Inc., a Viatris CompanyAvailable —
In shortage · October 19, 2026Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77)
Mylan Pharmaceuticals Inc., a Viatris CompanyAvailable —
In shortage · October 19, 2026Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77)
Mylan Pharmaceuticals Inc., a Viatris CompanyAvailable —
In shortage · October 19, 2026Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)
Mylan Pharmaceuticals Inc., a Viatris CompanyAvailable —
In shortage · October 19, 2026Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77)
Mylan Pharmaceuticals Inc., a Viatris CompanyAvailable —
In shortage · October 19, 2026Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)
Mylan Pharmaceuticals Inc., a Viatris CompanyAvailable —
In shortage · October 19, 2026Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09)
Amneal PharmaceuticalsAvailable —
In shortage · October 6, 2026+ 5 more products listed, currently available.
-
Lisdexamfetamine Dimesylate In shortage Limited supply 95 products · updated October 19, 2026
Psychiatry
Product Availability Expected supply / notes Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)
Sun Pharmaceutical Industries, Inc.Limited Estimated Recovery: TBD
In shortage · October 19, 2026Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)
Sun Pharmaceutical Industries, Inc.Limited Estimated Recovery: TBD
In shortage · October 19, 2026Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)
Sun Pharmaceutical Industries, Inc.Limited Estimated Recovery: TBD
In shortage · October 19, 2026Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)
Sun Pharmaceutical Industries, Inc.Limited Estimated Recovery: TBD
In shortage · October 19, 2026Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)
Sun Pharmaceutical Industries, Inc.Limited Estimated Recovery: TBD
In shortage · October 19, 2026Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 57664-047-88)
Sun Pharmaceutical Industries, Inc.Limited Estimated Recovery: TBD
In shortage · October 19, 2026Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)
Sun Pharmaceutical Industries, Inc.Limited Estimated Recovery: TBD
In shortage · October 19, 2026Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37)
Lannett Company, Inc.Limited Estimated recovery: October 2026
In shortage · October 15, 2026Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)
Elite Laboratories, Inc.Limited Estimated recovery: TBD
In shortage · October 15, 2026Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)
Elite Laboratories, Inc.Limited Estimated recovery: TBD
In shortage · October 15, 2026Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37)
Lannett Company, Inc.Limited Estimated recovery: October 2026
In shortage · October 15, 2026Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)
Elite Laboratories, Inc.Limited Estimated recovery: TBD
In shortage · October 15, 2026Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)
Elite Laboratories, Inc.Limited Estimated recovery: TBD
In shortage · October 15, 2026Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)
Elite Laboratories, Inc.Limited Estimated recovery: TBD
In shortage · October 15, 2026Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)
Elite Laboratories, Inc.Limited Estimated recovery: TBD
In shortage · October 15, 2026Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)
Elite Laboratories, Inc.Limited Estimated recovery: TBD
In shortage · October 15, 2026Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37)
Lannett Company, Inc.Limited Estimated recovery: October 2026
In shortage · October 15, 2026Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)
Hikma Pharmaceuticals USA, Inc.Limited Available on allocation
In shortage · October 14, 2026Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)
Hikma Pharmaceuticals USA, Inc.Limited Available on allocation
In shortage · October 14, 2026Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)
Hikma Pharmaceuticals USA, Inc.Limited Available on allocation
In shortage · October 14, 2026Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)
Hikma Pharmaceuticals USA, Inc.Limited Available on allocation
In shortage · October 14, 2026Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)
Hikma Pharmaceuticals USA, Inc.Limited Available on allocation
In shortage · October 14, 2026Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)
Hikma Pharmaceuticals USA, Inc.Limited Available on allocation
In shortage · October 14, 2026Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)
Solco Healthcare US, LLCLimited On allocation
In shortage · June 29, 2026Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)
Solco Healthcare US, LLCLimited On allocation
In shortage · June 29, 2026Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)
Solco Healthcare US, LLCLimited On allocation
In shortage · June 29, 2026Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)
Solco Healthcare US, LLCLimited On allocation
In shortage · June 29, 2026Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)
Solco Healthcare US, LLCLimited On allocation
In shortage · June 29, 2026Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)
Solco Healthcare US, LLCLimited On allocation
In shortage · June 29, 2026Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)
Solco Healthcare US, LLCLimited On allocation
In shortage · June 29, 2026Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)
Rhodes Pharmaceuticals L.P.Limited Estimated recovery: TBD
In shortage · June 24, 2026Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)
Rhodes Pharmaceuticals L.P.Limited Estimated recovery: TBD
In shortage · June 24, 2026Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)
Rhodes Pharmaceuticals L.P.Limited Estimated recovery: TBD
In shortage · June 24, 2026Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)
Rhodes Pharmaceuticals L.P.Limited Estimated recovery: TBD
In shortage · June 24, 2026Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)
Rhodes Pharmaceuticals L.P.Limited Estimated recovery: TBD
In shortage · June 24, 2026Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)
Hikma Pharmaceuticals USA, Inc.Limited Available on allocation
In shortage · May 12, 2026+ 59 more products listed, currently available.
-
Lysine Acetate, Leucine, Phenylalanine, Valine, Isoleucine, Methionine, Threonine, Tryptophan, Alanine, Arginine, Glycine, Histidine, Proline, Glutamic Acid, Serine, Aspartic Acid, and Tyrosi In shortage 2 products · updated October 19, 2026
Gastroenterology
Product Availability Expected supply / notes Plenamine, Injection, 0.15 (NDC 0264-4500-00)
B. Braun Medical Inc.Available —
In shortage · October 19, 2026Plenamine, Injection, 0.15 (NDC 0264-4500-05)
B. Braun Medical Inc.Available —
In shortage · October 19, 2026 -
Remifentanil Hydrochloride In shortage Some forms unavailable 9 products · updated October 19, 2026
Analgesia/Addiction
Product Availability Expected supply / notes Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)
Fresenius Kabi USA, LLCUnavailable Next release November 2026. Check wholesalers for inventory.
In shortage · October 15, 2026Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)
Hikma Pharmaceuticals USA, Inc.Unavailable Estimated recovery: TBD
In shortage · October 14, 2026Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)
Hikma Pharmaceuticals USA, Inc.Unavailable Estimated recovery: TBD
In shortage · October 14, 2026Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)
Hikma Pharmaceuticals USA, Inc.Unavailable Estimated recovery: TBD
In shortage · October 14, 2026+ 5 more products listed, currently available.
-
Sterile Water Irrigant In shortage Some forms unavailable 9 products · updated October 19, 2026
Gastroenterology, Other, Pediatric
Product Availability Expected supply / notes Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)
Otsuka ICU Medical LLCUnavailable Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
In shortage · October 16, 2026Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)
Otsuka ICU Medical LLCUnavailable Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
In shortage · October 16, 2026Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)
Otsuka ICU Medical LLCUnavailable Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
In shortage · October 16, 2026Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)
Otsuka ICU Medical LLCUnavailable Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
In shortage · October 16, 2026Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)
Baxter HealthcareLimited Estimated Recovery: January 2027
In shortage · October 16, 2026+ 4 more products listed, currently available.
-
Technetium Tc99m Pyrophosphate In shortage Some forms unavailable 2 products · updated October 19, 2026
Medical Imaging
Product Availability Expected supply / notes CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)
Sun Pharmaceutical Industries, Inc.Unavailable Estimated Recovery: TBD
In shortage · October 19, 2026CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)
Sun Pharmaceutical Industries, Inc.Unavailable Estimated Recovery: TBD
In shortage · October 19, 2026 -
Amino Acid In shortage 3 products · updated October 16, 2026
Gastroenterology
Product Availability Expected supply / notes Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)
Baxter HealthcareAvailable —
In shortage · October 16, 2026Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)
Baxter HealthcareAvailable —
In shortage · October 16, 2026PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg/100 mL; 320 mg/100 mL; 50 mg/100 mL; 1.44 g/100 mL (NDC 0338-0499-06)
Baxter HealthcareAvailable —
In shortage · October 16, 2026
Reading the list: a medicine stays on the FDA list while any of its products is short. "Available" next to a product means that particular strength or pack can currently be ordered. If your pharmacy cannot fill a prescription, ask the pharmacist or prescriber about another strength, form or an alternative — do not ration or stop a medicine on your own.
Source: FDA Drug Shortages Database, via openFDA. Updated here twice a day; last update October 31, 2026 14:40. openFDA data are not validated for clinical use — confirm with the FDA source or your pharmacist.